A pipeline for senolytics.

Area of Science:

• Cellular senescence
• Drug discovery
• Age-related diseases

Background:

• Senescent cells contribute to age-related diseases.
• Current senolytic drug screening uses in vitro induced senescence, which may not reflect in vivo conditions.
• Developing senolytics that target in vivo senescent cells is crucial.

Purpose of the Study:

• To establish a high-throughput drug screening pipeline for senolytic compounds using in vivo induced senescence.
• To identify novel senolytic compounds effective against specific in vivo senescent cell populations.
• To evaluate candidate senolytics for treating age-related diseases like idiopathic pulmonary fibrosis.

Main Methods:

• Development of a high-throughput screening pipeline for senolytic compounds.
• Induction of senescence in vivo.
• Screening of compounds using the developed pipeline.
• Identification of HSP90 inhibitor XL888 as a candidate senolytic.

Main Results:

• A novel pipeline for high-throughput screening of senolytics was established.
• Senescence was successfully induced in vivo.
• The HSP90 inhibitor XL888 was identified as a promising senolytic candidate.
• XL888 shows potential for treating idiopathic pulmonary fibrosis.

Conclusions:

• The developed in vivo senescence screening pipeline offers a more relevant approach for identifying senolytics.
• XL888 is a potential senolytic drug for idiopathic pulmonary fibrosis.
• This study paves the way for discovering targeted senolytics for various age-related conditions.